Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 10, 2023

BUY
$37.4 - $42.94 $18,326 - $21,040
490 Added 7.34%
7,168 $272,000
Q1 2023

Apr 19, 2023

BUY
$34.88 - $43.22 $7,848 - $9,724
225 Added 3.49%
6,678 $252,000
Q4 2022

Jan 13, 2023

BUY
$33.8 - $47.06 $218,111 - $303,678
6,453 New
6,453 $0

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Harbour Capital Advisors, LLC Portfolio

Follow Harbour Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbour Capital Advisors, LLC with notifications on news.